Standout Papers

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular ... 2014 2026 2018 2022 323
  1. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice (2014)
    Bo-Wen Lin, Nobutaka Koibuchi et al. Cardiovascular Diabetology

Immediate Impact

4 by Nobel laureates 55 standout
Sub-graph 1 of 23

Citing Papers

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
2024 Standout
Alternative splicing and related RNA binding proteins in human health and disease
2024 Standout
1 intermediate paper

Works of Bo-Wen Lin being referenced

Endothelial deletion of PTBP1 disrupts ventricular chamber development
2023
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone
2015

Author Peers

Author Last Decade Papers Cites
Bo-Wen Lin 203 426 181 350 32 1.1k
Yumei Zhan 356 666 222 156 21 1.4k
Nirav Dhanesha 128 470 146 165 51 1.2k
Minsuk Kim 364 441 75 452 40 1.2k
Qing Zhou 237 539 107 194 52 1.2k
John M. Ong 178 628 228 208 23 1.3k
Tamotsu Yokota 194 589 113 307 37 1.4k
Hiroe Toba 476 473 139 219 49 1.3k
Mauro Torti 240 479 148 101 39 1.4k
Paula-Anahi Arias-Loza 340 381 61 253 43 1.1k
Béatrice Jaspard‐Vinassa 195 629 136 235 35 1.2k

All Works

Loading papers...

Rankless by CCL
2026